These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14517707)

  • 1. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
    Silveira P; Vaz-da-Silva M; Almeida L; Maia J; Falcão A; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):603-9. PubMed ID: 14517707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa.
    Almeida L; Vaz-da-Silva M; Silveira P; Falcão A; Maia J; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
    Clin Neuropharmacol; 2004; 27(1):17-24. PubMed ID: 15090932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
    Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
    Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
    Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
    Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans.
    Almeida L; Soares-da-Silva P
    Drugs R D; 2003; 4(4):207-17. PubMed ID: 12848585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
    Soares-da-Silva P; Vieira-Coelho MA; Parada A
    Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects.
    Almeida L; Soares-da-Silva P
    J Clin Pharmacol; 2003 Dec; 43(12):1350-60. PubMed ID: 14615471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
    Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
    Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
    Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
    Dingemanse J; Jorga K; Zürcher G; Schmitt M; Sedek G; Da Prada M; Van Brummelen P
    Br J Clin Pharmacol; 1995 Sep; 40(3):253-62. PubMed ID: 8527287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
    Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
    Rocha JF; Sicard É; Fauchoux N; Falcão A; Santos A; Loureiro AI; Pinto R; Bonifácio MJ; Nunes T; Almeida L; Soares-da-Silva P
    Br J Clin Pharmacol; 2017 Mar; 83(3):540-553. PubMed ID: 27763682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
    Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
    Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
    Crevoisier C; Monreal A; Metzger B; Nilsen T
    Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.